- Home
- CRVS vs CRGX Comparison
CRVS vs CRGX Comparison
Compare CRVS & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRVS
- CRGX
- Stock Information
- Founded
- CRVS 2014
- CRGX 2021
- Country
- CRVS United States
- CRGX United States
- Employees
- CRVS N/A
- CRGX N/A
- Industry
- CRVS Biotechnology: Pharmaceutical Preparations
- CRGX
- Sector
- CRVS Health Care
- CRGX
- Exchange
- CRVS Nasdaq
- CRGX Nasdaq
- Market Cap
- CRVS 206.5M
- CRGX 213.5M
- IPO Year
- CRVS 2016
- CRGX 2023
- Fundamental
- Price
- CRVS $3.61
- CRGX $4.12
- Analyst Decision
- CRVS Strong Buy
- CRGX Hold
- Analyst Count
- CRVS 3
- CRGX 7
- Target Price
- CRVS $16.33
- CRGX $4.67
- AVG Volume (30 Days)
- CRVS 1.6M
- CRGX 779.6K
- Earning Date
- CRVS 05-08-2025
- CRGX 05-23-2025
- Dividend Yield
- CRVS N/A
- CRGX N/A
- EPS Growth
- CRVS N/A
- CRGX N/A
- EPS
- CRVS N/A
- CRGX N/A
- Revenue
- CRVS N/A
- CRGX N/A
- Revenue This Year
- CRVS N/A
- CRGX $58.18
- Revenue Next Year
- CRVS N/A
- CRGX N/A
- P/E Ratio
- CRVS N/A
- CRGX N/A
- Revenue Growth
- CRVS N/A
- CRGX N/A
- 52 Week Low
- CRVS $1.75
- CRGX $3.00
- 52 Week High
- CRVS $10.00
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- CRVS 50.22
- CRGX 45.87
- Support Level
- CRVS $3.46
- CRGX $3.78
- Resistance Level
- CRVS $4.53
- CRGX $4.32
- Average True Range (ATR)
- CRVS 0.28
- CRGX 0.21
- MACD
- CRVS 0.02
- CRGX -0.03
- Stochastic Oscillator
- CRVS 32.60
- CRGX 39.20
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platforms, and manufacturing are designed to directly address the limitations of approved chimeric antigen receptor (CAR) T-cell therapies. Its product includes CRG-023, an investigational tri-specific CAR T designed to address several known causes of relapse associated with existing CAR T-cell therapies such as loss of tumor antigen expression, loss of co-stimulation (e.g., via CD58/CD2 signaling) and T cell exhaustion. CRG-023 is designed to target the B-cell lineage antigens (CD19, CD20, CD22) via tri-cistronic expression of three distinct CARs from a single lentiviral vector.